Yilmaz, Gul RuhsarKaya, OnurInkaya, Ahmet CagkanUnal, OnurTemel, Esra NurluAkcam, Fusun ZeynepCetin, Emel Sesli2024-08-042024-08-0420231300-932X2602-2842https://doi.org/10.5578/flora.202401981https://search.trdizin.gov.tr/yayin/detay/1228184https://hdl.handle.net/11616/92954The first-line treatment for Pneumocystis jirovecii pneumonia (PCP) is trimethoprim-sulfamethoxazole (TMP-SMZ). However, some cases require alternative agents due to the side effects of TMP-SMZ. Treatment with TMP-SMZ was initiated in an HIV-positive patient with microbiologically confirmed PCP, who presented with acute renal failure on admission. On the third day of treatment, TMP-SMZ was discontinued due to worsening renal function. Subsequently, clindamycin was initiated in combination with caspofungin. Although caspofungin-based therapies were shown to be effective against Pneumocystis in animal models, clinical experience in humans is limited. The patient was treated successfully with clindamycin combined with caspofungin.eninfo:eu-repo/semantics/openAccessWordsPneumocystis jiroveciiClindamycinCaspofunginArticle29113914410.5578/flora.2024019811228184WOS:001258696800001N/A